DruSO-CU: Determinants of omalizumab drug survival in a long-term daily practice multicentre cohort of patients with Chronic Urticaria

This international, multi-center, retrospective cohort study aims to investigate effectiveness and safety of omalizumab in a large multicenter cohort of patients with CU by using drug survival analysis. Furthermore, this study aims to identify the determinants of drug survival.

Study type: multi-center daily practice cohort study

We intend to present the study results at international congresses (preferably EADV and/or EAACI) and to publish them in high impact peer-reviewed scientific journals. To become a coauthor, you need to participate in the project and contribute to sufficient patient recruitment (both quantity and quality), the interpretation of the study results and manuscript development. Participation is feasible for centers with CU patient populations treated with omalizumab of n > 100 and the guarantee that data can be provided for all patients, to avoid selection bias.

Deadline: finish patient inclusion; July 22nd, 2022 anticipated

Are you interested in participating in the study? Please visit our member’s areaor send an Email (h.rockmann@umcutrecht.nl) for additional information.

With the sixth consensus meeting on the international EAACI/GA²LEN/EuroGuiDerm guideline for urticaria fast approaching, Professor Marcus Maurer is joined by guideline development group member, Professor Torsten Zuberbier, who explains what we can expect from this new edition.

Read more

Patients with chronic conditions are increasingly seeking information from information and communications technologies (ICTs) to manage their health. As of yet, it is not known which general or specific ICTs patients use to obtain information on health-related topics and specifically on CU, or how patients perceive the currently available information via ICTs. Gaining knowledge on this is...

Read more

In cooperation with many experts, scientists and medthority, a podcast series on the subject of Urticara has been created under the title: All things urticaria. Further episodes are constantly being created. At Apple Podcasts you can currently find all available episodes. You can listen to them in your browser or in Apple Podcasts. Have fun with it....

Read more

Contact us

GA²LEN coordinating Office
c/o DGAKI
Robert-Koch-Platz 7
10115 Berlin, Germany

UCARE office
Laura Schwenner

info(at)ga2len-ucare.com